The Platelet IIb/IIIa Inhibitor Abciximab as Adjunctive Therapy in Carotid Stenting of Potential Thrombotic Lesions

Felipe A. Ceceña, David H. Hoelzinger, JESS A. MILLER, S. Abu‐Shakra

Journal of Interventional Cardiology · 1999 · 17 citations · 19 references

Concepts

Abstract

We evaluated the use of abciximab (ReoPro), a monoclonal glycoprotein (GP) IIb/IIIa inhibitor, in 45 patients and 49 carotid vessels undergoing stent placement for neurologically symptomatic, critical lesions of the common and/or internal carotid arteries. Our assessments included procedural success and clinical outcomes including stroke, myocardial infarction (MI), neurological death, and bleeding. There were no instances of minor or major stroke, Q‐wave or non‐Q‐wave MI, thrombocytopenia, or neurological death in the periprocedural in‐hospital period immediately poststenting to discharge, nor any neurological events related to the ipsilateral hemisphere or neurological death during follow‐up of up to 1 year, 6 months, and 30 days (30,10, and 5 patients, respectively). The hemoglnbin/hematocrit levels dropped in two patients, necessitating blood transfusions. Two patients died with multiple organ failure, and three more developed a non‐Q‐wave infarction at 4 months, 2 months, and 3 weeks poststenting, respectively.

References

19